In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence.

As for other hematological diseases, treatment of PCNSL today is based on two pillars: induction treatment and consolidation treatment. Listen to Dr Schrob describe her clinical experience and contributions to the international clinical trials that have shifted PCNSL prognosis from a disease with short life-expectancy if left untreated to a curable disease. And get inspired by Dr Schorb’s appeal to “stay tuned, stay in touch because your investigator-initiated ideas can make all the difference”. 

Guest: Dr Elisabeth Schorb

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe